Pfizer announced Friday that preliminary results from a study on its experimental oral antiviral pill ritonavir showed a nearly 90% reduction in hospitalization and death …
Pfizer announced Friday that preliminary results from a study on its experimental oral antiviral pill ritonavir showed a nearly 90% reduction in hospitalization and death in high-risk adults with COVID-19. The company said it will soon seek approval from the Food and Drug Administration (FDA) for the pill.
